

Mylan CEO to testify in hearing on EpiPen price increases

September 14 2016, by Mary Clare Jalonick



In this April 8, 2008 file photo, Heather Bresch, chief operating officer of Mylan Pharmacueticals, sits in her office in Canonsburg, Pa. Bresch will face lawmakers' questions at a hearing next week on steep price hikes for the company's life-saving EpiPen injector device. (AP Photo/Dale Sparks, File)

The head of the pharmaceutical company Mylan will face lawmakers' questions at a hearing next week on steep price increases for its life-saving EpiPen injector device.



Mylan CEO Heather Bresch and an official from the Food and Drug Administration will testify before the House Oversight and Government Reform Committee.

The committee's leaders said in a statement that there is "justified outrage" from families and schools struggling to pay for the emergency allergy shots. The price has grown to \$608 for a two-pack, an increase of more than 500 percent since 2007.

The chairman, GOP Rep. Jason Chaffetz of Utah, and the top Democrat, Rep. Elijah Cummings of Maryland, said they also will examine ways to encourage greater competition in the EpiPen market.

Several other committees are looking into the matter.

The leaders of the Senate Homeland Security and Governmental Affairs' investigations subcommittee said last week they have begun an inquiry into the company's pricing and competition practices. The Senate Aging Committee has requested briefings on the issue. The chairman of the Senate Judiciary Committee has written several letters to Mylan demanding answers.

Mylan's Bresch is the daughter of Sen. Joe Manchin, D-W.Va.

© 2016 The Associated Press. All rights reserved.

Citation: Mylan CEO to testify in hearing on EpiPen price increases (2016, September 14) retrieved 20 April 2024 from

https://medicalxpress.com/news/2016-09-mylan-ceo-testify-epipen-price.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.